OncoMatch/Clinical Trials/NCT05783570
To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307
Is NCT05783570 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies EU307 CAR-T Cell for advanced hepatocellular carcinoma.
Treatment: EU307 CAR-T Cell — To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307, Autologous Glypican 3 (GPC3) Targeted Chimeric Antigen Receptor T cell therapy in Patients with GPC3 Positive Advanced Hepatocellular Carcinoma who Have Failed Standard Therapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: GPC3 positivity by IHC
Confirmed GPC3 positivity by IHC based on a liver tissue sample
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy (atezolizumab plus bevacizumab, tyrosine kinase inhibitors, sorafenib, lenvatinib) — first- or second-line
refractory to first- or second-line standard therapy* with no other standard therapy available
Lab requirements
Blood counts
WBC ≥ 2,000 /μL; ANC ≥ 1,000 /μL; Platelet ≥ 80,000 /μL; Hemoglobin ≥ 9.0 g/dL; PT(INR) ≤1.5 x ULN
Kidney function
Serum creatinine ≤1.5 x ULN; Creatinine clearance (CrCl) ≥ 30 mL/min
Liver function
Albumin ≥ 2.8 g/dL; AST and ALT ≤ 5x ULN; Total bilirubin ≤ 2 x ULN; Child-Pugh score Class A or Class B(7)
Patients who have adequate bone marrow, liver, and kidney functions at the time of screening: WBC ≥ 2,000 /μL ANC ≥ 1,000 /μL Platelet ≥ 80,000 /μL Hemoglobin ≥ 9.0 g/dL Albumin ≥ 2.8 g/dL AST and ALT ≤ 5ⅹULN Total bilirubin ≤ 2 x ULN Serum creatinine ≤1.5 x ULN Creatinine clearance (CrCl) ≥ 30 mL/min PT(INR) ≤1.5 x ULN; Child-Pugh score Class A or Class B(7)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify